Prostate cancer
CRPC: treatment in daily clinical practice
Obiettivo della formazione: Gain insight into the appropriate selection of life-prolonging treatments for non-metastatic CRPC (nmCRPC) and metastatic CRPC (mCRPC).
Specializzazione: Urology, Medical oncology, Clinical oncology
Pubblico target: CME (basic, intermediate), Residents (senior)
Aggiornamento più recente: April 2023
Premessa:
The optimal treatment choice/sequence for an individual patient with castration-resistant prostate cancer (CRPC) is challenging. This topic is limited to patients with a castrate testosterone level. Bone-protective agents fall beyond the scope of this topic.
Regulatory approval status of drugs for CRPC discussed in this topic (indications limited to the CRPC setting, status 3 April 2023)
